Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 30, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6025

Shown on this page

Current sort

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

weight loss overweight metabolic syndrome bariatric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 205–216 of 6,025 matching trials for Obesity.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more

Conditions: Obesity, Cerebrovascular Function, Immune Cells Activity
Interventions: High intensity inspiratory muscle strength training, Low intensity; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Obesity or Overweight
Interventions: Petrelintide, Placebo; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Anniston, Alabama • Port Orange, Florida • Nashville, Tennessee

Conditions: Overweight and Obesity
Interventions: Active Implicit Priming, Control Implicit Priming, Food Exposure Task; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity, Overweight
Interventions: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 49
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Overweight, Obesity, Type 2 Diabetes
Interventions: Cagrilintide, Placebo (matched to Cagrilintide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more

Conditions: Obesity or Overweight, Cardiovascular Disease
Interventions: Petrelintide, Placebo; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Anniston, Alabama • Los Angeles, California • Port Orange, Florida

Conditions: Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
Interventions: Prolonged Fasting Intervention, EDUCATION CONTROL; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more

Conditions: Obesity or Overweight, Type 2 Diabetes
Interventions: Petrelintide, Placebo; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Manassas, Virginia

Conditions: Overweight, Obesity
Interventions: Coach Share On, Group Share On, Friend/Family Share On, Coach Share Off, Group Share Off, Friend/Family Share Off, Behavioral Weight Loss Treatment; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Childhood Obesity
Interventions: Phentermine, Placebo; Drug
Lead sponsor: Russell McCulloh, MD; Network
Eligibility: 12 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Wilmington, Delaware • Louisville, Kentucky • Baton Rouge, Louisiana + 5 more

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

How Obesity studies are organized in the registry

Filter and sort this condition

Live official records

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Respiratory Muscle Training to Improve Cerebrovascular and Immune Function

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

PROFAST Intervention in Precursor Multiple Myeloma

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss

Phentermine's Impact on Treatment in Teens

About this Obesity clinical trials directory page